immatics biotechnologies GmbH

About us
Immatics Biotechnologies is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.
Our transformative product candidates are – best in class – Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics’​ proprietary and world-leading XPRESIDENT® technology.

Our mission is to bring the power of T-cell redirecting immunotherapies to cancer patients.

Quick Facts
150 Team members
>100 Targets covering 20 major solid and liquid tumors
About 80% of discovered targets are novel
2 proprietary technology platforms
8 proprietary development programs, thereof 2 in the clinic in 2017
Multiple partnered programs
Raised more than $230m in cash in five financings